MELPHALAN (ALKERAN)

Course overview

Melphalan is U.S. FDA-approved as palliative treatment for multiple myeloma, and for nonresectable epithelial ovarian carcinoma (P.O. only). It must be used cautiously in older patients, and in patients with preexisting bone marrow suppression or moderate/severe renal impairment. This continuing education module is designed to give the reader/learner an increased understanding of melphalan. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.